Liquid Biopsy Market

---

Global Liquid Biopsy Market is expected to reach at USD 14.09 Billion by 2032, at a CAGR of 24.3% from 2023 to 2032.

---

Liquid biopsy is a type of non-invasive test for cancer. It is a type of laboratory test used to detect the presence of cancer cells and other genetic material in the bloodstream. It is a minimally invasive test used to detect cancer cells and other genetic material in the bloodstream. It can detect the presence of cancer cells in the blood or monitor the progress of cancer treatment. It is also used to monitor the side effects of cancer treatment.

---

The global liquid biopsy market is driven by the growing prevalence of cancer, rising demand for minimally invasive testing procedures, and technological advancements in liquid biopsy.

---

Furthermore, increasing investments in liquid biopsy research and development (R&D), growing awareness about liquid biopsy procedures, and rising demand for personalized medicine are expected to drive market growth.

---

However, the high cost of liquid biopsy tests and the lack of trained professionals are expected to restrain market growth.

---

The global liquid biopsy market is segmented based on products, technology, application, and end user.

---

Based on product, the market is segmented into assays and instruments.

---

The assay segment is further divided into circulating tumor cells (CTCs), circulating nucleic acids (CNAs), and exosomes.

---

The instruments segment is further divided into PCR-based, sequencing-based, and other instruments.

---

Based on technology, the market is segmented into PCR-based technology, sequencing-based technology, and other technologies.

---

Based on application, the market is segmented into cancer diagnostics, cancer prognostics, and cancer therapeutics.

---

Based on end user, the market is segmented into hospitals and clinics, diagnostic laboratories, and research centers.

---

Geographically, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA.

---

The key players operating in this market include Biocept, Inc., Guardant Health, Inc., F. Hoffmann-La Roche AG, Qiagen N.V., Illumina, Inc., Trovagene, Inc., Myriad Genetics, Inc., Menarini Silicon Biosystems, Inc., Bio-Rad Laboratories, Inc., and Sysmex Corporation.

---

Key Benefits

---

The study provides an in-depth analysis of the global liquid biopsy market and current & future trends to elucidate the imminent investment pockets.

---

Information about key drivers, restrains, and opportunity and their impact analysis on the market size is provided in the report.

---

Porter’s five forces analysis illustrates the potency of buyers and suppliers operating in the industry.

---

The quantitative analysis of the global liquid biopsy market

---

Liquid Biopsy Market Segmentation

---

By Product

---

• Assays

---

o Circulating Tumor Cells (CTCs)

---

o Circulating Nucleic Acids (CNAs)

---

o Exosomes

---

• Instruments

---

o PCR-based Instruments

---

o Sequencing-based Instruments

---

o Other Instruments

---

By Technology

---

• PCR-based Technology

---

• Sequencing-based Technology

---

• Other Technologies

---

By Application

---

• Cancer Diagnostics

---

• Cancer Prognostics

---

• Cancer Therapeutics

---

By End User

---

• Hospitals and Clinics

---

• Diagnostic Laboratories

---

• Research Centers

---

By Region

---

• North America

---

o U.S.

---

o Canada

---

o Mexico

---

• Europe

---

o UK

---

o Germany

---

o France

---

o Italy

---

o Spain

---

o Rest of Europe

---

• Asia-Pacific

---

o Japan

---

o China

---

o India

---

o Australia

---

o South Korea

---

o Rest of Asia-Pacific

---

• LAMEA

---

o Brazil

---

o Saudi Arabia

---

o South Africa

---

o Rest of LAMEA

---